EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy

Markus Falk iD, Eva Willing, Stefanie Schmidt, Stefanie Schatz iD, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brueckl iD

Current Oncology · 2023

DOI: 10.3390/curroncol30020130 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2023. Verfasst von Markus Falk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Histopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany. Hauptthemen laut MEDLINE: Immunoconjugates, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Förderverein des Tumorzentrums Erlangen”, FAU Erlangen, W. Lutz Stiftung, Nuremberg, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-targeted therapy is currently the subject of several studies in lung cancer and other solid tumors using either tyrosine kinase inhibitors (TKI) or targeted-antibody–drug conjugates. We describe a 61-year-old female patient with HER2 mutated adenocarcinoma of the lungs who received chemo-immunotherapy, followed by trastuzumab deruxtecan (T-DXd) and third-line Ramucirumab/Docetaxel at disease progression. Plasma ctDNA monitoring was obtained at 12 timepoints during therapy and revealed HER2 mutation allele frequencies that corresponded to the clinical course of disease. HER2-targeted T-DXd therapy resulted in a profound clinical response and may be an option for NSCLC patients carrying an activated HER2 mutation. Longitudinal liquid biopsy quantification of the underlying driver alteration can serve as a powerful diagnostic tool to monitor course of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesCarcinoma, Non-Small-Cell LungLung NeoplasmsFemaleHumansMiddle AgedErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedLiquid BiopsyCamptothecinTrastuzumab

Stichwörter der Autor:innen

HER2 mutationdisease monitoringliquid biopsytrastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedImmunoconjugatestrastuzumab deruxtecanCamptothecinTrastuzumab

Autor:innen und Institutionen

  • Institute for Histopathology Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
  • Department of Radiology, Paracelsus Medical University, General Hospital Nurnberg, Ernst-Nathan-Str.1, 90419 Nuremberg, Germany.
  • Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nurnberg, Ernst-Nathan-Str.1, 90419 Nuremberg, Germany.

ORCID-Profile: Markus Falk, Stefanie Schatz, Wolfgang M Brueckl

Förderung

  • “Förderverein des Tumorzentrums Erlangen”
  • FAU Erlangen
  • W. Lutz Stiftung, Nuremberg, Germany

Zitieren

APA

Falk, M., Willing, E., Schmidt, S., Schatz, S., Galster, M., Tiemann, M., Ficker, J. H., & Brueckl, W. M. (2023). Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current Oncology. https://doi.org/10.3390/curroncol30020130

Vancouver

Falk M, Willing E, Schmidt S, Schatz S, Galster M, Tiemann M, et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current Oncology. 2023. doi:10.3390/curroncol30020130

BibTeX
@article{Falk2023,
  author = {Falk, Markus and Willing, Eva and Schmidt, Stefanie and Schatz, Stefanie and Galster, Marco and Tiemann, Markus and Ficker, Joachim H and Brueckl, Wolfgang M},
  title = {Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30020130}
}
Kostenlos starten →